DeepMed Research

Chinese Academy of Medical Sciences Peking Union Medical College Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Thalidomide, Cyclophosphamide and Dexamethasone for Recurrent/Refractory Adult Langerhans Cell Histiocytosis

Phase 2

Conditions: Langerhans Cell Histiocytosis

Interventions: Drug: thalidomide combined with dexamethasone and cyclophosphamide

First Posted Date: 2019-10-09

Last Posted Date: 2021-06-08

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 20

Registration Number: NCT04120519

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China

The Effect of Frailty to Perioperative Complications in the Elderly

Completed

Conditions: Fragility
Intraoperative Hypotension
Perioperative Complication

First Posted Date: 2019-10-09

Last Posted Date: 2025-01-28

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 166

Registration Number: NCT04120012

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Clinical Application of Laparo-endoscopic Single-site Surgery and Natural Orifice Transluminal Endoscopic in Gynecology

Conditions: Cervical Cancer, Endometrial Cancer，Endometrial Lesion & Adnexal Lesion，Ectopic Pregnancy & Infertility，Pelvic Obstructive Disorder & Genital Tract Deformity

First Posted Date: 2019-09-20

Last Posted Date: 2019-09-20

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 9000

Registration Number: NCT04096872

Locations: 🇨🇳
Gless-Notes, Beijing, Beijing, China

Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia

Phase 2

Completed

Conditions: Autoimmune Hemolytic Anemia
Autoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia

Interventions: Drug: combination of a single dose anti-CD20 antibody and bortezomib

First Posted Date: 2019-09-10

Last Posted Date: 2024-04-26

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 33

Registration Number: NCT04083014

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

A Clinical Study on the Treatment of Cerebral Small Vascular Disease

Not Applicable

Conditions: Cerebral Small Vessel Diseases

Interventions: Drug: Butylphthalide Soft Capsules
Drug: placebo Soft Capsules

First Posted Date: 2019-09-04

Last Posted Date: 2019-09-04

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 300

Registration Number: NCT04078204

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China

IA14 Induction in Young Acute Myeloid Leukemia

Phase 2

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Idarubicin and cytarabine induction

First Posted Date: 2019-08-28

Last Posted Date: 2021-06-08

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 42

Registration Number: NCT04069208

Locations: 🇨🇳
Xinxin Cao, Beijing, Beijing, China

Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer

Phase 2

Conditions: Recurrent Platinum-resistant Ovarian Cancer

Interventions: Drug: Camrelizumab (SHR-1210)
Drug: Apatinib

First Posted Date: 2019-08-28

Last Posted Date: 2021-03-16

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 28

Registration Number: NCT04068974

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China

Nutritional Deficiencies About Recurrent Miscarriage

Conditions: Abortion, Habitual
Nutritional Status

Interventions: Diagnostic Test: Detection of niacin and other vitamins in plasma

First Posted Date: 2019-08-22

Last Posted Date: 2022-03-15

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 1000

Registration Number: NCT04064931

Locations: 🇨🇳
Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, Beijing, China

Comparing the Impact of Multimodal Prehabilitation to Aerobic Training on Patients Undergoing Thoracoscopic Lobectomy

Not Applicable

Conditions: Perioperative
Thoracoschisis
Prehabilitation
Lung Cancer
Lobectomy
Recovery

Interventions: Behavioral: Aerobic training group
Other: Multimodal prehabilitation group

First Posted Date: 2019-08-08

Last Posted Date: 2022-12-28

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 100

Registration Number: NCT04049942

Locations: 🇨🇳
PekingUnionMedicalCollegeHospital, Beijing, Beijing, China

Camrelizumab Combined With Apatinib for Recurrent Resistant GTN

Phase 2

Completed

Conditions: Gestational Trophoblastic Disease

Interventions: Drug: Apatinib
Drug: Camrelizumab

First Posted Date: 2019-08-06

Last Posted Date: 2021-07-30

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 20

Registration Number: NCT04047017

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy